Assessment of body mass index in patients with chronic hepatitis C who received an effective antiviral therapy
Aim. To evaluate the body mass index (BMI) in patients with chronic hepatitis C (CHC) with different stages of liver fibrosis and steatosis who received effective antiviral therapy (AVT). Materials and methods. The study included 278 CHC patients with a sustained virologic response (SVR) at the e...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2023-10-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/607400/136047 |
| _version_ | 1827768324231004160 |
|---|---|
| author | Kristina R. Dudina Petr A. Belyy Igor V. Maev Elena A. Klimova Svetlana A. Shutko Olga O. Znoyko Nikolay D. Yuschuk |
| author_facet | Kristina R. Dudina Petr A. Belyy Igor V. Maev Elena A. Klimova Svetlana A. Shutko Olga O. Znoyko Nikolay D. Yuschuk |
| author_sort | Kristina R. Dudina |
| collection | DOAJ |
| description | Aim. To evaluate the body mass index (BMI) in patients with chronic hepatitis C (CHC) with different stages of liver fibrosis and steatosis who received effective antiviral therapy (AVT).
Materials and methods. The study included 278 CHC patients with a sustained virologic response (SVR) at the end of treatment. In addition to assessing the investigational data to determine the clinical status of the patient, we calculated BMI (following the World Health Organization guidelines) and determined the severity of liver fibrosis (F) and steatosis (S) using transient elastography. The patients were assessed at the start of antiviral therapy, after 6 months from the moment SVR was confirmed, and then every 12 to 24 months.
Results. By the end of the study, the mean patient age was 49 years, 53% of them were men, and 34% of the patients were obese. Excessive weight gain was registered in 17% (n=48) of the cases, with 60% newly diagnosed with Class 1 to 2 obesity. Both before the start of AVT and years after reaching SVR, the mean BMI corresponded to the reference pre-obesity values, the liver steatosis was significantly more often absent in normal BMI; on the contrary, fatty liver (predominantly S2 to S3) was registered in individuals with elevated BMI (p0.0001). After the long-term period following a successful therapy, Stage F4 liver fibrosis patients were mainly diagnosed with obesity (80% versus 44% before AVT; p=0.0010).
Conclusion. The high proportion of patients with elevated BMI and liver steatosis seen years after a successful CHC therapy indicates a continued risk of progression of chronic liver disease. Such patients should be advised on how important it is to change their lifestyle to reduce overweight and prevent weight gain. We also need long-term assessments of how liver steatosis changes over time and what are the outcomes associated with post-SVR increase in BMI. |
| first_indexed | 2024-03-11T12:10:44Z |
| format | Article |
| id | doaj.art-680b4c71fe4a415bae2c985faf6f5a01 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-03-11T12:10:44Z |
| publishDate | 2023-10-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-680b4c71fe4a415bae2c985faf6f5a012023-11-07T14:05:12Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422023-10-0195863464010.26442/00403660.2023.08.20231878334Assessment of body mass index in patients with chronic hepatitis C who received an effective antiviral therapyKristina R. Dudina0https://orcid.org/0000-0002-3901-3138Petr A. Belyy1https://orcid.org/0000-0001-5998-4874Igor V. Maev2https://orcid.org/0000-0001-6114-564XElena A. Klimova3https://orcid.org/0000-0003-4319-8144Svetlana A. Shutko4https://orcid.org/0000-0003-4670-5818Olga O. Znoyko5https://orcid.org/0000-0002-4965-596XNikolay D. Yuschuk6https://orcid.org/0000-0002-4003-4622Yevdokimov Moscow State University of Medicine and DentistryYevdokimov Moscow State University of Medicine and DentistryYevdokimov Moscow State University of Medicine and DentistryYevdokimov Moscow State University of Medicine and DentistryYevdokimov Moscow State University of Medicine and DentistryYevdokimov Moscow State University of Medicine and DentistryYevdokimov Moscow State University of Medicine and DentistryAim. To evaluate the body mass index (BMI) in patients with chronic hepatitis C (CHC) with different stages of liver fibrosis and steatosis who received effective antiviral therapy (AVT). Materials and methods. The study included 278 CHC patients with a sustained virologic response (SVR) at the end of treatment. In addition to assessing the investigational data to determine the clinical status of the patient, we calculated BMI (following the World Health Organization guidelines) and determined the severity of liver fibrosis (F) and steatosis (S) using transient elastography. The patients were assessed at the start of antiviral therapy, after 6 months from the moment SVR was confirmed, and then every 12 to 24 months. Results. By the end of the study, the mean patient age was 49 years, 53% of them were men, and 34% of the patients were obese. Excessive weight gain was registered in 17% (n=48) of the cases, with 60% newly diagnosed with Class 1 to 2 obesity. Both before the start of AVT and years after reaching SVR, the mean BMI corresponded to the reference pre-obesity values, the liver steatosis was significantly more often absent in normal BMI; on the contrary, fatty liver (predominantly S2 to S3) was registered in individuals with elevated BMI (p0.0001). After the long-term period following a successful therapy, Stage F4 liver fibrosis patients were mainly diagnosed with obesity (80% versus 44% before AVT; p=0.0010). Conclusion. The high proportion of patients with elevated BMI and liver steatosis seen years after a successful CHC therapy indicates a continued risk of progression of chronic liver disease. Such patients should be advised on how important it is to change their lifestyle to reduce overweight and prevent weight gain. We also need long-term assessments of how liver steatosis changes over time and what are the outcomes associated with post-SVR increase in BMI.https://ter-arkhiv.ru/0040-3660/article/viewFile/607400/136047chronic hepatitis csustained virologic responsebody mass indexliver steatosisnon-alcoholic fatty liver disease |
| spellingShingle | Kristina R. Dudina Petr A. Belyy Igor V. Maev Elena A. Klimova Svetlana A. Shutko Olga O. Znoyko Nikolay D. Yuschuk Assessment of body mass index in patients with chronic hepatitis C who received an effective antiviral therapy Терапевтический архив chronic hepatitis c sustained virologic response body mass index liver steatosis non-alcoholic fatty liver disease |
| title | Assessment of body mass index in patients with chronic hepatitis C who received an effective antiviral therapy |
| title_full | Assessment of body mass index in patients with chronic hepatitis C who received an effective antiviral therapy |
| title_fullStr | Assessment of body mass index in patients with chronic hepatitis C who received an effective antiviral therapy |
| title_full_unstemmed | Assessment of body mass index in patients with chronic hepatitis C who received an effective antiviral therapy |
| title_short | Assessment of body mass index in patients with chronic hepatitis C who received an effective antiviral therapy |
| title_sort | assessment of body mass index in patients with chronic hepatitis c who received an effective antiviral therapy |
| topic | chronic hepatitis c sustained virologic response body mass index liver steatosis non-alcoholic fatty liver disease |
| url | https://ter-arkhiv.ru/0040-3660/article/viewFile/607400/136047 |
| work_keys_str_mv | AT kristinardudina assessmentofbodymassindexinpatientswithchronichepatitiscwhoreceivedaneffectiveantiviraltherapy AT petrabelyy assessmentofbodymassindexinpatientswithchronichepatitiscwhoreceivedaneffectiveantiviraltherapy AT igorvmaev assessmentofbodymassindexinpatientswithchronichepatitiscwhoreceivedaneffectiveantiviraltherapy AT elenaaklimova assessmentofbodymassindexinpatientswithchronichepatitiscwhoreceivedaneffectiveantiviraltherapy AT svetlanaashutko assessmentofbodymassindexinpatientswithchronichepatitiscwhoreceivedaneffectiveantiviraltherapy AT olgaoznoyko assessmentofbodymassindexinpatientswithchronichepatitiscwhoreceivedaneffectiveantiviraltherapy AT nikolaydyuschuk assessmentofbodymassindexinpatientswithchronichepatitiscwhoreceivedaneffectiveantiviraltherapy |